{
    "Clinical Trial ID": "NCT00191451",
    "Intervention": [
        "INTERVENTION 1: ",
        "  HER2+",
        "  Human Epidermal growth factor Receptor 2 positive: Gemcitabine + Carboplatin + Herceptin.",
        "  Gemcitabine: Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion); Carboplatin: Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion); Herceptin: Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion). Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion).",
        "INTERVENTION 2: ",
        "  HER2- (Taxane-)",
        "  Human Epidermal growth factor Receptor 2 negative: Gemcitabine + Carboplatin. (Taxane-naive patients).",
        "  Gemcitabine: Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion); Carboplatin: Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion)."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Diagnosis of metastatic breast cancer",
        "  Able to visit the doctor's office at least every 14 days during the actual treatment",
        "  Able to care for yourself, even if you cannot work or participate in other normal activities",
        "  Your blood results must be adequate for therapy.",
        "  If you are a female of childbearing potential and test negative for pregnancy, use a reliable method of birth control during and for three months following the last dose of study drug.",
        "Exclusion Criteria:",
        "  Have received gemcitabine, paraplatin, or trastuzumab for your cancer.",
        "  Be pregnant or breastfeeding",
        "  Have cancer to the brain and has not been treated",
        "  Have another active cancer besides breast cancer",
        "  Have received stem cell or bone marrow transplant for hematologic (blood type) cancer"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Overall Tumor Response",
        "  Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.",
        "  Time frame: baseline to disease progression/recurrence (up to 3.5 years)",
        "Results 1: ",
        "  Arm/Group Title: HER2+",
        "  Arm/Group Description: Human Epidermal growth factor Receptor 2 positive: Gemcitabine + Carboplatin + Herceptin.",
        "  Gemcitabine: Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion); Carboplatin: Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion); Herceptin: Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion). Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion).",
        "  Overall Number of Participants Analyzed: 50",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Complete Response (CR): 6",
        "  Partial Response (PR): 26",
        "  Stable Disease (SD): 12",
        "  Progressive Disease (PD): 4",
        "Not Evaluable (NE): 2",
        "Results 2: ",
        "  Arm/Group Title: HER2- (Taxane-)",
        "  Arm/Group Description: Human Epidermal growth factor Receptor 2 negative: Gemcitabine + Carboplatin. (Taxane-naive patients).",
        "  Gemcitabine: Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion); Carboplatin: Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).",
        "  Overall Number of Participants Analyzed: 47",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Complete Response (CR): 0",
        "  Partial Response (PR): 13",
        "  Stable Disease (SD): 20",
        "  Progressive Disease (PD): 12",
        "Not Evaluable (NE): 2"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 10/50 (20.00%)",
        "  Anaemia 0/50 (0.00%)",
        "  Febrile neutropenia 0/50 (0.00%)",
        "  Neutropenia 0/50 (0.00%)",
        "  Thrombocytopenia 0/50 (0.00%)",
        "  Diastolic dysfunction 0/50 (0.00%)",
        "  Tachycardia 0/50 (0.00%)",
        "  Intestinal obstruction 0/50 (0.00%)",
        "  Nausea 1/50 (2.00%)",
        "  Oesophageal spasm 0/50 (0.00%)",
        "  Oesophagitis 0/50 (0.00%)",
        "  Retching 0/50 (0.00%)",
        "Adverse Events 2:",
        "  Total: 11/48 (22.92%)",
        "  Anaemia 4/48 (8.33%)",
        "  Febrile neutropenia 0/48 (0.00%)",
        "  Neutropenia 2/48 (4.17%)",
        "  Thrombocytopenia 2/48 (4.17%)",
        "  Diastolic dysfunction 1/48 (2.08%)",
        "  Tachycardia 1/48 (2.08%)",
        "  Intestinal obstruction 0/48 (0.00%)",
        "  Nausea 0/48 (0.00%)",
        "  Oesophageal spasm 1/48 (2.08%)",
        "  Oesophagitis 0/48 (0.00%)",
        "  Retching 1/48 (2.08%)"
    ]
}